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1. Introduction 
Over the past decade, it has become clear many of the age-related health problems of men, 
that have hitherto been treated using different medical disciplines, are actually inter-related 
and require a more integrative approach in the aging male. Lower urinary tract symptoms 
(LUTS) may serve as an example. LUTS consists of storage, voiding, and post micturition 
symptoms affecting the lower urinary tract. Storage symptoms (daytime frequency, 
nocturia, urgency, incontinence) are experienced during the storage phase of the bladder. 
Voiding symptoms (weak stream, splitting or spraying, abdominal straining, hesitancy, 
intermittency, terminal dribble) are experienced during the voiding phase. Post-micturition 
symptoms (feeling of incomplete emptying, post micturition dribble) are experienced 
immediately after micturition. Individuals with LUTS often experience urinary incontinence 
(UI) or overactive bladder (OAB) symptoms. OAB is a subset of storage LUTS defined as 
urgency, with or without urgency UI, usually with frequency and nocturia. Men may report 
one or any combination of the symptoms and LUTS, including UI and OAB, have 
detrimental effects on health-related quality of life. 
The prevalence of LUTS increases from 8% in the fourth decade of life to more than 70% in 
the seventh decade. In a large population-based cross-sectional survey the prevalence of 
storage LUTS (men, 51.3%; women, 59.2%) was greater than that for voiding (men, 25.7%; 
women, 19.5%) and post micturition (men, 16.9%; women, 14.2%) symptoms combined 
(Irwin et al., 2008).   
Once symptoms arise, their progress is variable and unpredictable with about one third of 
patients improving, one third remaining stable and one third deteriorating. LUTS may point to 
serious pathology of the urogenital tract but are often nonspecific and large studies of patients 
have failed to show any correlation between LUTS and a specific diagnosis. An all-
encompassing view of LUTS that focuses on the lower urinary tract as an integrated functional 
unit, but simultaneously reflects pathophysiology in the body as a whole, is more likely to 
improve a clinician’s ability to manage the symptoms and therefore improve patient outcomes. 
Benign prostatic hyperplasia (BPH), which occurs more frequently with aging, is the most 
common cause of LUTS in middle-aged and elderly men, although many other diseases 
such as detrusor muscle weakness and/or instability, urinary tract infection, chronic 
prostatitis, urinary stone, prostate cancer, bladder cancer, neurological disease, e.g. multiple 
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The role of testosterone in voiding function remains obscure, although it plays a definite role 
in the etiopathogenesis of BPH. The indirect relation could obscure an interrelation between 
circulating levels of testosterone and symptoms of LUTS at a statistically significant level 
which nevertheless is biologically plausible. This chapter will discuss possible relationships 
between androgens and LUTS 
2. Sex hormone involvement in the etiopathognesis of BPH 
The two factors that are generally accepted to play a role in the etiopathogenesis of BPH are 
aging and androgen. While serum testosterone level steadily decreases after 40 years of age, 
the prevalence of histologic BPH in autopsy studies rises from approximately 20% in men 
aged 41-50 to 50% in men aged 51-60, and to over 90% in men older than 80 (Berry et al., 
1984). An enlarged prostate (BPE) is detectable in approximately on half of the patients with 
histologic evidence of BPH. The gradual reduction of plasma testosterone in middle-aged 
and older men from mid-life onwards coincides paradoxically with the time when there is 
progressive growth of the prostate, a highly androgen-dependent organ. In the prostate, 
testosterone is converted into the more potent androgen, dihydrotestosterone (DHT) by 5ǂ 
reductase. It is thought that DHT has a central role in BPH development and maintenance 
because the inhibition of 5ǂ reductase activity is associated with decreased serum DHT 
concentration and decreased prostate size (Figure 1).  
 
 
Fig. 1. Androgen regulation of cell growth in the prostate cell 
Observations and clinical studies in men have clearly demonstrated that BPH is under 
endocrine control. Men castrated before puberty (eunuchs) develop neither BPH nor BPE, 
and individuals with an inherited deficiency of 5ǂ reductase have only a vestigial prostate 
gland. Castration results in the regression of established BPH and improvement in urinary 
symptoms. Administration of a gonadotropin releasing hormone (GnRH) analog in men 
reversibly shrinks established BPH, resulting in objective improvement in urinary flow rate 
and subjective improvement in symptoms. Finally, clinical experience with finasteride, a 5ǂ 
reductase type II inhibitor has documented the relevance of DHT on prostate size 
(Marberger, 1998). Despite these convicting data, the correlation between androgens and 
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prostate volume in elderly men is less pronounced. Joseph et al. (2002) reported that a large 
prostate volume was marginally associated with increased total testosterone level in 
African-American men, but Meikle et al. (1997) found an inverse correlation between 
prostate volume and total testosterone level in 214 male twins based on white populations. 
Others have not found a significant association between total testosterone level and prostate 
volume. Partin et al. (1991) correlated 23 hormonal factors, including total testosterone/free 
testosterone to BPH volume assessed histologically. After correcting for age, the BPH 
volume correlated significantly with free testosterone, but not total testosterone. If not 
corrected for age, neither testosterone nor free testosterone correlated with BPH volume.  
It has been demonstrated that 5 alpha-reductase activity (Bruchovsky et al., 1998), and 
androgen receptor levels (Barrack et al., 1983) increase with aging, which means that 
prostatic cells may gradually become more sensitive to DHT during aging, and that this 
stimulates cell replication in the prostate. Estradiol has been hypothesized to potentiate the 
effects of androgens in inducing BPH by inducing the androgen receptor, which thereby 
sensitizes the prostate to free testosterone. In dogs, estrogens have been shown to induce the 
androgen receptor, alter steroid metabolism resulting in higher levels of intraprostatic DHT, 
inhibit cell death when given in the presence of androgens, and stimulate stromal collagen 
production. Schatzl et al. (2000) found hypogonadism in approximately one fifth of elderly 
men with LUTS but it had no impact on LUTS status, PSA level, prostate volume, 
uroflowmetry, or endocrine parameters. In contrast to testosterone, they observed an age-
related increase in estradiol (+0.86 pg/mL per decade), the only hormone to correlate with 
prostate volume, thus suggesting its significance for BPH and BPE. Gann et al. (1995) 
assessed the relation of steroid hormone levels with subsequent surgical treatment for BPH 
among participants in the Physicians Health Study and found a strong correlation for 
increasing risk and serum estrogen levels. The relevance of estrogens is underscored by the 
fact that, within the prostate, the highest concentrations have been detected in the stroma, 
the predominant tissue found in BPH. The rate-limiting step in estrogen biosynthesis is the 
conversion of androgens to estrogens, which is catalyzed by the enzyme aromatase. This 
enzyme is expressed in the human prostate and is regulated by follicle-stimulating hormone 
(FSH). The recent demonstration of a coexpression of gonadotropin hormones and their 
corresponding receptors in the human prostate suggests that FSH receptor activation acts in 
an endocrine fashion by way of age-dependent, elevated FSH (Schatzl et al., 2000). 
Alternatively, FSH might act in a para-autocrine fashion by way of locally produced FSH, 
potentially stimulating aromatase activity. 
From the above mentioned facts, the age-related growth of the prostate cannot be explained 
by a mere increase or decrease in serum androgens. Schultheiss et al. (2004) reviewed 
previous studies and concluded that the link between androgens and age-related growth of 
the prostate might be explained by a shift of the hormonal ratio (e.g. the androgen/estrogen 
ratio), the changing intraprostatic hormonal level, or a modified action of hormones and 
their respective receptors, as well as of intraprostatic enzymes (e.g. 5ǂ reductase). 
Additional large studies are needed to evaluate the above mechanisms. 
3. Testosterone deficiency linked to LUTS 
Historically, bladder outlet obstruction (BOO), LUTS, and BPH has been considered to be 
almost synonymous, however, an increasing number of studies now demonstrate that the 
correlations between these parameters are weak and symptoms may arise from many 
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different etiologies. Although LUTS is commonly attributed to BOO caused by BPE, LUTS is 
not associated with BOO in a third to a half of men (Figure 2) and furthermore, the severity 
of LUTS secondary to BPH is not necessarily correlated with prostate volume (Chang et al., 
2009). Some men with greatly enlarged glands may have little obstruction and few 
symptoms while others with prostate glands less enlarged have more outlet obstruction and 
severe symptoms. Asian men have a smaller prostate than Caucasians, but may have similar 
or higher symptom scores and a more impaired quality of life (Homma et al., 1997).  
 
 
Fig. 2. Correlation between lower urinary tract symptoms (LUTS) and histologic benign 
prostatic hyperplasia (BPH), benign prostatic enlargement (BPE) and bladder outlet 
obstruction (BOO)  
Many studies have tried to establish a relationship between sex steroids and BPH, but a few 
studies have analyzed the relationship between circulating testosterone and LUTS. At the 
epidemiological level, an association between central obesity in adulthood, the metabolic 
syndrome, erectile dysfunction (ED) and LUTS has been established (Rohrmann et al., 2007). 
A common denominator of the ailments is lower-than-normal testosterone levels occurring 
in a significant proportion of elderly men. However, there is no consensus on possible 
effects of testosterone on LUTS. Schatzl et al. (2003) found that hypogonadism was seen 
approximately one-fifth of elderly men with LUTS, but it had no impact on symptom status. 
Litman et al. (2007) found an inverse correlation between symptoms of LUTS and plasma 
total and bioavailable testosterone but this relationship disappeared after statistical 
adjustment for age. Roberts et al. (2004) reported a negative association between total 
testosterone and American Urological Association Symptom Index (AUA-SI) but not with 
bioavailable testosterone. Miwa et al. (2008) noted an inverse association of free testosterone, 
but not total testosterone, to International Prostate Symptom Score (IPSS). Recently, author 
(2009) found free and bioavailable testosterone had significant negative relationships with 
IPSS total scores and subscores for voiding symptoms even after adjusting for age, prostate 
total volume and transitional zone volume, high sensitivity C-reactive protein (CRP) and 
homeostasis model assessment of insulin resistance (HOMA-IR). In addition, free and 
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≥20) even after adjusting for confounding factors (Figure 3). However, the odds ratio of 





Fig. 3. Blood levels of free testosterone (pg/ml) depending on degree of LUTS severity 
(Adopted from Chang, et al., 2009) 
 
 
Fig. 4. Odds ratios (95% Cl) of total (T), free (FT) and bioavailable (BT) testosterone, and sex 
hormone binding globulin (SHBG)  on log scales for prediction of severe LUTS (Adopted 
from Chang, et al., 2009) 
A few studies have investigated serum DHT and LUTS. Of the studies examining this 
association, DHT has not been related with LUTS or BPH in prospective (Meigs et al., 2001; 
Gann et al., 1995) or cross sectional studies (Platz et al., 1999; Litman et al., 2007). Trifiro et 
al. (2010) found there was a weak (and unadjusted) association only, suggesting an increase 
in mean serum DHT concentration among men with LUTS compared with those without. 
However, serum DHT may not be an ideal measurement of intraprostatic androgen 
concentrations, as serum DHT does not necessarily correlate to prostate tissue 
concentrations of DHT. Because of this observation, the serum DHT metabolites 17 beta-
diol-glucuronide and androrstanediol glucuronide (AAG) are often used to estimate DHT 
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metabolites and testosterone to DHT metabolite ratios to be directly associated with LUTS 
or BPH (Kristal et al., 2008; Platz et al., 1999). Kristal et al (2008) showed stronger 
associations as a ratio suggesting that the testosterone : DHT metabolite or testosterone : 
DHT ratio may therefore be a more sensitive marker of LUTS/BPH than either hormone 
individually. Platz et al. (1999) estimated the risk of BPH and severe LUTS in relation to 
testosterone, DHT, estradiol and AAG in 300 men with severe LUTS. There was a positive 
relation with AAG and an inverse one with estradiol for the risk of BPH surgery/LUTS, the 
correlations persisting even after adjusting for steroid hormones and sex hormone binding 
globulin (SHBG).  
A study showed at the 105th Annual Scientific Meeting of the AUA that as testosterone 
levels decreased, LUTS severity increased and maximum flow rate decreased, while prostate 
volume remained the same as hormone levels decreased (Sauver, et al., 2010). In another 
study to determine the relationship between androgens, LUTS and urodynamic variables of 
BOO in patients with LUTS/BPH, free testosterone was negatively correlated with detrusor 
pressure at the end of urinary flow (closure detrusor pressure) and pressure at the 
maximum urinary flow rate (Qmax) (Koritsiadis et al., 2008). Mean closure detrusor 
pressure and detrusor pressure at Qmax differed significantly between patients with low 
and normal free testosterone levels. Detrusor overactivity (DO) was noted in patients who 
had significantly lower free testosterone levels than those with no DO. Although several 
cross-sectional and prospective studies showed no consensus of association of testosterone 
with LUTS or BPH, it is notable that no studies have as yet reported an increased risk of 
LUTS with higher testosterone. 
In the rabbit bladder outlet obstruction study, bladder dysfunction is mainly mediated by 
three cellular processes; 1) progressive denervation, 2) cellular mitochondria malfunction, 3) 
dysregulation of intracellular calcium storage and release from the sarcoplasmic reticulum 
(SR). Biomarkers for these three functions are calcium adenosine triphosphatase (ATPase) for 
calcium release, citrate synthase for mitochondrial function, and choline acetyl-transferse for 
cholinergic innervations (Juan et al., 2007). Bladder contraction can be divided into phasic and 
tonic period. The phasic response depends on the adenosine triphosphate (ATP) concentration 
in the bladder wall, whereas the tonic phase requires mitochondrial oxidative activity to 
generate energy. Castration of adult male rabbits resulted in a significant decrease in the 
activities of the mitochondria specific enzyme, citrate synthase of the bladder body and base, 
muscle and mucosa, urethra and corpora, while choline acetyl-transferse activity and calcium 
ATPase activity showed different responses depending on the sites (Juan et al., 2007).  
Preliminary evidence indicates that men with LUTS benefit from testosterone treatment, and 
pilot studies have also shown that testosterone therapy has a positive effect on LUTS in late-
onset hypogonadism. A study found that the higher plasma levels of testosterone generated 
with oral testosterone undecanoate than with testosterone gel (50mg/day) were more effective 
in reducing the score on the IPSS, probably indicating that there is a relationship between 
plasma levels of testosterone and their effects on LUTS (Yassin et al., 2008). Although this 
inverse association is contrary to the commonly held clinical opinion that higher serum 
androgen levels may worsen clinical LUTS and BPH, the risk would not applicable to 
normalization of the serum testosterone levels in late onset hypogonadism. Clinical trials are 
needed to confirm that testosterone replacement therapy in older men does not increase the 
risks of LUTS or clinical BPH. It would also be significant to explore whether normalization of 
plasma testosterone has an adjunctive therapeutic effect to the more established 
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pharmacological treatment modalities of LUTS as in an adjunctive therapeutic effect of 
testosterone supplement to phosphodiesterase type 5 (PDE5) inhibitors for ED treatment 
accompanied by the testosterone deficiency (Buvat et al., 2011; Blute et al., 2009). 
There is ample evidence from many epidemiological studies that LUTS and ED are strongly 
linked, independently of age. ED assessed by a questionnaire, International Index of Erectile 
Function (IIEF) score was strongly related to LUTS severity. When controlling for age, LUTS 
severity was by far the strongest predictor of erectile function, with an odd ratio for severe 
vs mild LUTS of 8.99 followed by diabetes, 3.01; cardiac disease, 2.17; hypertension, 1.83 and 
hyperlipidemia, 1.57 (McVary., 2006). The fact that LUTS severity is the strongest predictor 
of ED suggests that LUTS and ED may share their underlying causes and the underlying 
causes may explain the reasons why severity of LUTS does not correlates with prostate size. 
Although a direct causal relationship is not established yet, four pathophysiological 
mechanisms can explain the relationship. These include 1) insulin resistance and autonomic 
hyperactivity, 2) alteration in nitric oxide bioavailability, 3) Rho-kinase 
activation/endothelin pathway, 4) pelvic atherosclerosis, all of which are known to be 
androgen-dependent. 
4. Insulin resistance and autonomic hyperactivity 
It was proposed that LUTS is a part of the metabolic syndrome which includes 
hyperglycemia, obesity, dyslipidemia and hypertension. Recently, testosterone deficiency 
has captured attention to be a possible risk factor of metabolic syndrome. The basis of this 
concept came from increased insulin resistance found in both hypergonadotropic and 
hypogonadotropic hypogonadism. Patients of un-treated Klinefelter's syndrome, compared 
with control subjects, showed a significantly higher prevalence of metabolic risk factors 
(Bojesen et al., 2006). GnRH agonist-treated men with prostate cancer also showed 
significantly decreased insulin sensitivity (Smith et al., 2006). Long-term survivors of 
testicular cancer have an increased risk for cardiovascular events 10 or more years after 
chemotherapy (Huddart et al., 2003). Nuver et al. (2005) found lower testosterone associated 
with a higher body mass index (BMI) pretreatment and a larger BMI increase during follow-
up in testicular cancer survivors following cisplatin–based chemotherapy than controls, 
suggesting testosterone may play a role in the development of the metabolic syndrome. 
Plasma testosterone levels decline with aging in healthy men and features of the metabolic 
syndrome also show age-related deteriorations, suggesting that testosterone is an important 
regulator of insulin sensitivity in men. There are lots of evidences that late onset 
hypogonadism is associated with metabolic syndrome. Blouin et al. (2006) investigated 
whether this decline or the aging process per se accounts for the risk of metabolic syndrome. 
They observed that patients with a high testosterone level were more likely to have fewer 
than three components of metabolic syndrome than those with a low testosterone level. 
Author (2009) also found that HOMA-IR correlated negatively with serum total, free and 
bioavailable testosterone. Studies showed that blood levels of insulin and metabolic risk 
factors increased with lower testosterone levels in middle aged men (Laaksonen, et al., 
2003). And patients with metabolic syndrome had significantly lower serum testosterone 
level than those without metabolic syndrome. Men who developed both metabolic 
syndrome and diabetes mellitus at 11-year follow-up were especially likely to have low 
testosterone levels already at baseline (Laaksonen, et al., 2004). Pitteloud et al (2005a) 
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demonstrated men with hypogonadal testosterone levels were twice as insulin resistant as 
their eugonadal counterparts and 90% fulfill criteria for the metabolic syndrome.  
Recent studies provide insight into the role of mitochondrial function in the pathogenesis of 
insulin resistance. Mitochondria have a critical role in Ca2+ buffering in bladder smooth 
muscle. Pitteloud et al. (2005a) demonstrated testosterone levels were positively correlated 
not only with insulin sensitivity but also with genetic (oxidative phosphorylation gene 
expression) and functional (maximal aerobic capacity) markers of mitochondrial function, 
suggesting a novel molecular mechanism whereby testosterone might modulate insulin 
sensitivity in men. Pitteloud et al. (2005b) found in another study that insulin resistance was 
associated with a decrease in Leydig cell testosterone secretion by evaluating the 
hypothalamic-pituitary-gonadal axis in men with a spectrum of insulin sensitivity.  
The most common cause of ED is penile vascular insufficiency. This is usually part of a 
generalized endothelial dysfunction and is related to several conditions, including type 2 
diabetes mellitus, hypertension, hyperlipidemia, and obesity, of which conditions underlie 
the pathophysiology of metabolic syndrome. There is evidence from multiple 
epidemiological studies that LUTS and ED are correlated, independent of age or 
comorbidities as diabetes or hypertension. The prevalence of LUTS was 72% in men with ED 
versus 38% in those without ED. And the presence of LUTS was a risk factor of ED. 
Therefore, men seeking care for one condition should always be screened for complaints of 
the other condition.  
Metabolic risk factors induce testosterone deficiency. Obesity-related conditions such as 
obstructive sleep apnea, insulin resistance and type 2 diabetes mellitus are independently 
associated with decreased plasma testosterone. Possible mechanisms include decreased LH 
pulse amplitude, inhibitory effects of estrogen at the hypothalamus and pituitary and the 
effects of leptin and other peptides centrally and on Leydig cells. Diabetes induces testicular 
oxidative stress and damage, 
Summing up, metabolic syndrome is a risk factor of LUTS and ED and may reduce the 
blood level of testosterone. Contrariwise, testosterone deficiency may be a causative factor 
of metabolic risk factors and may accompany LUTS and ED. LUTS is a risk factor of ED and 
vice versa. This interrelationship suggests that these ailments may be a symptom complex 
and may share the underlying causes (Figure 5).  
 
 
Fig. 5. Interrelationship between metabolic syndrme (MS) testosterone deficiency (TD) lower 
urinary tract symptom (LUTS) and erectile dysfunction (ED) 
However, previous studies on the relationship between androgens and insulin sensitivity in 
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used. One explanation for this discrepancy is the SHBG is mediating the link between 
testosterone and insulin sensitivity. Proponents of the use of free testosterone argue that it is 
the best index of androgenicity in insulin-resistant men given the low SHBG levels that pertain 
in this setting (Plymate et al., 1988). Another explanation is that the assays used to measure 
free testosterone have serious methodological limitations (Matsumoto & Bremner, 2004).  
In a recent study of the epidemiological relationship between metabolic syndrome and 
LUTS, it was hypothesized that metabolic syndrome is associated with overactivity of the 
autonomic nervous system, and that insulin resistance, a key element of metabolic 
syndrome, might be responsible. Hyperinsulinemia promotes endothelin-1 (ET-1) secretion 
through mitogen-activated protein (MAP)-kinase pathway leading to increase in smooth 
muscle contraction. In addition, it activates sympathetic nerve system contributing to 
further increase in the contraction. Overactivity of the autonomic nervous system is 
supposedly not responsible for the development of LUTS, but rather is believed to play a 
key role in increasing LUTS severity above an intrinsic basal intensity (McVary et al., 2005; 
Kasturi et al., 2006). 
The studies of Meusburger & Keast (2001) and Keast et al. (2002) have provided elegant 
demonstrations on the potential role of androgens in maintaining the structure and function 
of many pelvic ganglion neurons. Giuliano et al. (1993) suggested that testosterone acting 
peripherally to the spinal cord enhances the erectile response of the cavernous nerve. Traish 
et al. (2007) showed that testosterone treatment of castrated animals restored the cavernosal 
nerve fibers and myelin sheath structure, similar to that observed in the sham group. 
Considering these reports and the hypothesis that noradrenaline and ǂ1-AR that mediate 
adrenergic contraction of smooth muscles in the prostate, bladder neck, urethra and corpus 
cavernosum, contribute to the common link, testosterone deficiency could be a causative 
factor of LUTS via autonomic hyperactivity.   
Another possible mechanism includes a direct relaxation effect of testosterone on smooth 
muscle cells, a change in the number of receptors for sympathetic affecter molecules or a 
change in sensitivity of smooth muscle cell ǂ-adrenergic receptors (ARs). Comparative 
binding and functional studies of lower genitourinary tissues have demonstrated that ǂ1-
ARs are abundant in the bladder base and prostate but spare in the bladder body (Lepor & 
Shapiro, 1984). In certain human arteries, ǂ1-AR expression increases and the relative 
proportion of ǂ1-AR subtypes is modulated by aging (Rudner et al., 1999). These changes 
might be happening as well in the human prostatic, bladder and erectile tissue. The 
contractile response of the cavernosal strips of older men with ED was greater than for those 
isolated from younger men with ED, suggesting that aging has a role in adrenergic 
sensitivity in patients with ED (Christ et al., 1991). It has also been suggested that ǂ1-ARs 
are up-regulated in patients with LUTS associated with BPH, resulting in increased smooth 
muscle tone in the prostatic capsule and bladder neck (Medina et al., 1999). 
Theoretically, selective ǂ1-AR antagonists are ideally suited for the treatment of the 
dynamic component of bladder outlet obstruction, because the resistance along the bladder 
outlet can be selectively reduced without impairing detrusor contraction. Virtually, ǂ1-AR 
antagonists have been widely used in practice for treating symptomatic BPH/LUTS. Despite 
the clinical availability of ǂ1-AR antagonists for treating LUTS, as yet it is not possible to 
provide a comprehensive picture of the impact of testosterone on ǂ1- ARs. While androgen 
effect on central and peripheral nervous system are well known, the local effect of androgen 
on bladder and urethra has not been extensively studied. Even reports on the density of ǂ1-
ARs after castration are not consistent. Takyu (1993) found the density of ǂ1-ARs in rabbit 
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proximal urethra decreased after castration and testosterone supplementation restored the 
densities of ǂ1-ARs to control levels. Morita et al. (1992) reported that ǂ1-adrenergic and 
muscarinic cholinergic receptor densities decreased significantly after castration. Yono et al 
(2006) found the density of ǂ1-ARs in the rat prostate decreased with aging. Because the 
percent of muscle density shows no significant change throughout life in the rat prostate 
(Moriyama et al., 1995), the age related decrease in the density of ǂ1-ARs appears to result 
from direct down-regulation of ǂ1-AR protein. Auger-Pourmarin et al. (1998) presented that 
testosterone administration produced a 23% decrease of ǂ1-AR density, likely by an increase 
of prostatic glandular epithelium and a decrease in the relative proportion of smooth 
muscle, thus of ǂ1-AR density. Lacey et al. (1996) found there was an apparent increase in 
ǂ1-AR density in dog prostate after castration which returned to baseline with testosterone 
replacement. However, the increase in ǂ1-ARs density resulted from relative increases in the 
ratio of smooth muscle to epithelium rather from direct up-regulation of ǂ1-AR protein. 
Lastly, recent studies provided an evidence that the inflammatory infiltrates, which are 
frequently found in and around nodules of BPH (Rohrmann et al, 2005), elevate serum CRP 
concentration, a non-specific marker of inflammation. Furthermore, the presence of 
metabolic syndrome might mediate intraprostatic inflammation because of its association 
with an elevated serum CRP concentration, which would link metabolic syndrome to 
symptomatic BPH (Rohrmann  et al., 2005). 
5. Alteration in nitric oxide bioavailability 
It is widely accepted that NO, which is synthesized from its precursor L-arginine via NO 
synthase (NOS), is important in the relaxation of corpus cavernosum smooth muscle and 
vasculature. By activating gualnylate cyclase, with resultant elevation of cyclic guanylate 
monophosphate (cGMP), NO results in a lowering of intracellular calcium and smooth 
muscle relaxation. cGMP is an important secondary messenger of NO involved in 
modulating the contractility of various smooth muscles. It stimulates protein kinase G, 
which in turn initiates phosphorylation of membrane-bound proteins at the potassium 
channels. This leads to potassium ion outflow into the extracellular space resulting in 
hyperpolarization. Hyperpolarization leads to closure of the L-type calcium channels 
subsequently resulting in a decrease in the intracellular Ca++ ion concentration and 
consequent smooth muscle cell relaxation. PDE plays important roles in this process by 
modulating the levels of cGMP and their duration of action (Traish et al., 2007) (Figure 6). 
NO is also present in the human prostate and bladder and putatively modulates smooth 
muscle tone. NOS activity has been reported to be highest in the prostatic urethra, 
intermediate in the bladder neck, and less pronounced in detrusor muscle. It has been 
reported that NOS expression, and thus NO production, of the prostate is reduced in the 
transition zone of the prostate in BPH compared with normal prostate (Bloch et al., 1997). 
The proposed reduction in expression of NOS isoforms results in increased smooth muscle 
cell contractile forces at the bladder neck and prostatic urethra leading to the subsequent 
development of LUTS or LUTS without BPH. On the other hand, reduced NOS/NO results 
in smooth muscle cell proliferation and may result in structural changes in the prostate and 
simultaneously increased contraction and affects outlet resistance and bladder compliance 
(Figure 7). Histochemical staining and immunohistochemistry confirmed dense nitrinergic 
innervations of glandular epithelium, fibromuscular stroma and blood vessels in the normal 
human prostate. The nitrinergic innervations is also less in hyperplastic human prostate 
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Fig. 6. Potential regulation of nitric oxide synthase (NOS) and hosphodiesterase type 5 
(PDE5) by androgens (Adopted fromTraish, et al., 2007) 
It is known that the lower urinary and genital tracts are embryologically and anatomically 
closely related, and that both are sensitive to sex steroids. A preponderance of evidence 
reports a role for androgens in regulating the expression and activity of NOS isoforms in the 
corpus cavernosum in animal models. In castrated animals, testosterone and DHT 
administration restored the erectile response and NOS expression in penis. It can be 
speculated that if testosterone participates in erectile mechanisms by modulating NOS and 
phosphodiesterase type 5 (PDE5), a similar interaction might be found in the lower urinary 
tract, given that the same enzymes and androgen receptors are also present. 
 
 
Fig. 7. NOS/NO theory for LUTS/ED (Adopted from McVary, et al., 2006) 
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Jones & Schoenberg (1985) suggested that aging itself might be an underlying cause of DO, 
besides BOO. In experimental studies, the inhibition of NO production causes bladder 
hyperactivity in rats in vivo (Persson et al., 1992), indicating a possible relation with changes 
in NOS activity in the lower urinary tract. Koritsiadis et al. (2008) found men with no DO 
had higher free testosterone levels, and all hypogonadal patients had DO, providing 
evidence that a decline in androgen levels might be a causative factor in DO, by triggering 
overactivity in an otherwise pathological bladder.  
PDE5 hydrolyzes cGMP in vascular and cavernous smooth muscle into GMP. Activation of 
PDE5 terminates NO-induced, cGMP-mediated smooth muscle relaxation. In penile tissue, 
the balance between the intracellular levels of cGMP and GMP is primarily regulated by the 
activities of NOS and PDE5. Thus, it is likely that any disruption in the expression or activity 
of these enzymes will lead to pathophysiology. Castration has been shown to induce the 
expression and activity of PDE5 in rabbits and rats, and androgen supplementation has been 
shown to up-regulate the expression and activity of PDE5 (Zhang et al., 2005; Morelli et al., 
2004). Further, administration of PDE inhibitor to castrated animals has little effect on the 
intracavernosal pressure in response to pelvic nerve stimulation (Zhang et al., 2005), 
suggesting that androgens are critical not only for regulating NOS activity, but also in 
modulating PDE5 activity. The presence of PDE in the urinary bladder was identified in 
studies of the rat (Qiu, et al., 2001) and the human (Werkstrom, et al., 2006).  
A recent study, investigating PDE5 expression and activity in the human bladder, elegantly 
demonstrated that PDE5 regulates smooth muscles tone of the bladder. Vardenafil appeared 
to block PDE5 activity, and therefore, may be a possible therapeutic option for bladder 
dysfunction by ameliorating irritative LUTS. The study also found that castration decreased, 
and testosterone supplementation restored, PDE5 gene expression in rat bladder (Morelli, et 
al., 2009). Meanwhile, a large number of clinical studies have convincingly shown that PDE 
inhibitors have a beneficial effect on LUTS. Sairam et al (2002) found the overall trend in the 
IPSS was towards improvement after treatment with sildenafil. In a recent 12-week global 
dose-finding study conducted in 1058 men with BPH-LUTS, tadalafil was associated with 
statistically significant and clinically meaningful improvements in multiple measures of 
LUTS, including quality of life and ED improvement, compared to placebo (Roehrborn et 
al., 2008).  Kim et al (2011) reported men with BPH-LUTS treated with tadalafil 5 mg once 
daily experienced a reduction in BPH-LUTS which was comparable to tamsulosin. 
6. Rho-kinase activation/endothelin activity  
Smooth muscle contraction has been attributed to an increase in the intracellular calcium 
concentration. However, some regulatory mechanisms can modify the sensitivity of 
contractile and regulatory proteins to calcium, leading to a smooth muscle contraction 
without changing intracellular calcium concentration (Somlyo A.P. & Somlyo A.V., 2000). 
One of these mechanisms is the Rho-kinase pathway, which is thought to be a major 
calcium-sensitizing mechanism in smooth muscle. The Rho-kinase is activated by a G-
protein, RhoA, thought to be coupled to excitatory ǂ1-adrenoceptors. The major contractile 
process in bladder is under acetylcholine control, through the activation of M3 muscarinic 
receptors. RhoA/Rho-kinase calcium sensitization pathway plays a major role in 
maintaining the contractile actions in bladder smooth muscle tone. Rees et al. (2003) found 
that a specific inhibitor of Rho-kinase, Y-27632, decreased the proliferation of human and rat 
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prostatic smooth muscle cells, and inhibited noradrenergic contractions elicited by electrical 
field stimulation and exogenous phenylephrine in rat prostatic tissue. 
In many pathological cases, hyperactivity of Rho/Rho-kinase signaling has been observed. 
Increased Rho-kinase activity, and consequently increased calcium sensitivity of the 
contractile machinery, can be found in the detrusor of rabbits with partial BOO (Bing et al., 
2003) and in the corpus cavernosum smooth muscle of rabbits with partial BOO (Chang et 
al., 2005). Increased smooth muscle myosin basal phosphorylation necessary for smooth 
muscle contraction in the corpus cavernosum smooth muscle of partial BOO, mediated via 
an increase in Rho-kinase expression/activity, would be expected to make the corpus 
cavernosum smooth muscle more difficult to relax, which suggests that the RhoA/Rho-
kinase pathway as being involved in the mechanism for LUTS-associated ED. 
In various animal species estrogen receptors are shown to be expressed in central nervous 
structures involved in micturition (VanderHorst et al., 2001), as well as in the bladder and 
urethra (Williams & Papka, 1996; Makela et al., 2000). Chavalmane et al. (2010) found that 
estrogen supplementation significantly increased the relaxing response of carbacol-
precontracted rat bladder strips to Y-27632, an inhibitor of Rho-kinase. On the contrary, 
testosterone administration in the same animal model did not increase responsiveness to Y-
27632, but even reduced it. This was in apparent contrast with the observation in isolated 
human bladder cells, where testosterone mimicked estrogen effects. However, in human 
bladder cells co-incubation with letrozole, an inhibitor of aromatase, reverted all the 
testosterone-induced effects. In addition, DHT, a non-aromatizable androgen, did not 
substantially stimulate smooth muscle gene expression and cell motility. These findings 
suggest that active aromatization is operating in human bladder cells and that estrogen and 
not androgen receptors are involved in stimulating cell migration and expression of genes 
related to the smooth muscle phenotype. In contrast to human bladder, rat bladder does not 
express aromatase/CYP19A1 mRNA and testosterone presumably acts only through the 
androgen receptors. These data indicate that estrogen, more than androgen, receptors up-
regulate Rho/Rho-kinase signaling and might have a role in calcium sensitization in human 
male bladder and androgens have the opposite effect. Clinical studies showing that 
androgen deficiency is associated with male bladder instability are in keeping with this 
view. Since an altered estrogen/androgen ratio characterizes several physiological and 
pathological conditions, often associated to bladder hyperactivity and LUTS, it is possible 
that a relative hyperesterogenism might induce bladder overactivity, through an activation 
of the Rho/Rho-kinase pathway. 
The actions of several factors beside noradrenaline (e.g. endothelin-1, angiotensin II), 
possibly involved in the increased smooth muscle activity found in both LUTS/BPH and 
ED, are dependent on Rho-kinase activity that acts downstream from these receptors 
(Anderson, 2003). Although the exact mechanisms by which angiotensin II elicits its cellular 
effects are not known, the mechanism of action of angiotensin II in the cells is related to the 
Rho/Rho-kinase pathway. While estradiol did not change the number of human aortic 
endothelial cells secreting endothelin-1 but decreased the number of secreting cells 
stimulated with angiotensin-II, testosterone induced an increase in the number of cells 
secreting endothelin-1 and up-regulated endothelin-1 mRNA, indicating that testosterone, 
estradiol and angiotensin-II have parallel effects on the production of endothelin-1 (Pearson 
et al., 2008).  
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7. Pelvic atherosclerosis 
Various studies show that bladder dysfunction can be caused by ischemia and suggest that 
atherosclerosis and hypercholesterolemia might be associated with LUTS. Ischemia in rabbit 
urinary bladder caused a marked reduction in the compliance and capacity of the bladder 
(Gill et al., 1988). Azadzoi et al. (1999) found that atherosclerosis-induced chronic bladder 
ischemia increased transforming growth factor-ǃ1 expression in the bladder leading to 
fibrosis, smooth muscle atrophy and non-compliance. Hypercholesterolemia also interfered 
with bladder structure and compliance but to a significantly lesser extent compared with 
chronic bladder ischemia. It is known atherosclerosis and hypercholesterolemia are 
associated with low serum androgen levels. Bladder outlet obstruction results in bladder 
hypertrophy which induces ischemia. Levin et al. (1997) hypothesized that this leads to a 
release of intracellular calcium, leading to activation of specific enzymes and generation of 
free radicals. These then attack the membranes of nerves, sarcoplasmic reticulum and 
mitochondria.  
In two cross-sectional studies of elderly men, intima-media thickness (IMT), an indicator of 
general atherosclerosis, was associated with lower testosterone levels (Hak et al., 2002; van 
den Beld et al., 2003). In a prospective population-based study, free but not total, 
testosterone levels were inversely related to IMT (Muller et al., 2004). In a logistic regression 
model adjusted for the confounding effect of cardiovascular risk factors, men with 
testosterone levels in the lowest quintile (<9.0 nmol L-1) had an independent OR =1.51 
(P=0.015) of being in the highest IMT quintile (Svartberg et al., 2006). Besides the possible 
modulating effect of testosterone on cardiovascular disease risk factors, a few other possible 
explanations for the association between testosterone and atherosclerosis have been 
suggested. A direct beneficial effect of testosterone on plaque development, probably 
mediated by the vascular androgen receptor has been reported in an animal study (Hanke et 
al., 2001). Testosterone has also been shown to enhance endothelium-independent and 
endothelium-dependent vasodilation (Kang et al., 2002 )  
8. Conclusion 
Many studies have tried to establish a relationship between sex steroids and BPH, but a few 
studies have analyzed the relationship between circulating testosterone and LUTS. 
Although there is no consensus on possible effects of testosterone on LUTS, endogenous 
testosterone may have a beneficial effect on the lower urinary tract function, and 
testosterone deficiency may provide a pathophysiologic basis for the link between LUTS. 
Preliminary evidence indicates that men with LUTS benefit from testosterone treatment. 
Four pathophysiological mechanisms can explain the relationship; insulin resistance and 
autonomic hyperactivity, alteration in NO/NOS/PDE activity, Rho-kinase 
activation/endothelin pathway, pelvic atherosclerosis, all of which are known to be 
androgen-dependent.  
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